



LUND UNIVERSITY

Array-based comparative genomic hybridization characterization of cytogenetically polyclonal myeloid malignancies.

Davidsson, Josef; Heidenblad, Markus; Borg, Åke; Johansson, Bertil

Published in:
Cancer Genetics and Cytogenetics

DOI:
[10.1016/j.cancergencyto.2006.03.002](https://doi.org/10.1016/j.cancergencyto.2006.03.002)

2006

[Link to publication](#)

Citation for published version (APA):
Davidsson, J., Heidenblad, M., Borg, Å., & Johansson, B. (2006). Array-based comparative genomic hybridization characterization of cytogenetically polyclonal myeloid malignancies. *Cancer Genetics and Cytogenetics*, 169(2), 179-180. <https://doi.org/10.1016/j.cancergencyto.2006.03.002>

Total number of authors:
4

General rights

Unless other specific re-use rights are stated the following general rights apply:
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

Read more about Creative commons licenses: <https://creativecommons.org/licenses/>

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

LUND UNIVERSITY

PO Box 117
221 00 Lund
+46 46-222 00 00

This is an author produced version of a paper published in Cancer Genetics and Cytogenetics. This paper has been peer-reviewed but does not include the final publisher proof-corrections or journal pagination.

Citation for the published paper:

Davidsson J, Heidenblad M, Borg A, Johansson B.

"Array-based comparative genomic hybridization characterization of cytogenetically polyclonal myeloid malignancies"
Cancer Genetics and Cytogenetics, 2006, Vol: 169, Issue: 2, pp. 179-80.
<http://dx.doi.org/10.1016/j.cancergencyto.2006.03.002>

Access to the published version may require journal subscription.

Published with permission from: Elsevier

Array-based comparative genomic hybridization characterization of cytogenetically polyclonal myeloid malignancies

The paradigmatic view in cancer biology today is that neoplasia has a monoclonal origin [1]. Occasionally, however, clones with different aberrations are found within individual tumors [2]. Whether such a cytogenetic polyclonality represents a true polyclonal origin of the different clones or whether they share a submicroscopic primary change, indicating a monoclonal origin, is unknown. Recently, we reported that multicolor fluorescence in situ hybridization did not reveal any primary cryptic changes in fourteen investigated polyclonal hematologic malignancies [3]. We concluded that other methods to screen for common cryptic changes, such as genome-wide array-based comparative genomic hybridization (aCGH), perhaps could be fruitful.

We have performed aCGH on 6 polyclonal myeloid malignancies, comprising four acute myeloid leukemias and two myelodysplastic syndromes (Table 1), using a 32K array set, consisting of 32,433 BAC clones covering 98% of the human genome, produced at the SWEGENE DNA microarray resource center (Lund University, Sweden). In all hybridizations, male reference genomic DNA was used (Promega, Madison, WI). Analyses of the microarray images were performed with GenePix Pro 4.0 software (Axon Instruments, Foster City, CA). To identify imbalances, the MATLAB toolbox CGH plotter was used, applying moving mean average of 3 clones and amplification/deletion limits of $\log_2 > 0.2$. Mapping of gains or losses was based on identification as such by the CGH plotter and by visual inspection of the \log_2 ratios. All these analyses were performed in the BioArray Software Environment database [4].

Apart from 15 copy number polymorphisms [5], not expected to be involved in the leukemogenic process, no cryptic changes, linking the different clones together, were found in the aCGH analyses. However, it should be stressed that this does not necessary exclude the presence of such abnormalities. First, a large admixture of normal, nonneoplastic cells could hamper detection of common cryptic changes. Second, aCGH does not identify balanced abnormalities; thus, if the cryptic change is a translocation or inversion it would remain undetected. A final possibility could, of course, be that the cytogenetic polyclonality really indicates a true polyclonal origin of the tumor cells.

Acknowledgments

This study was supported by grants from the Swedish Cancer Society, the Ingabritt and Arne Lundberg Foundation, and the Knut and Alice Wallenberg Foundation via the SWEGENE program.

Josef Davidsson^a

Markus Heidenblad^a

Åke Borg^{b,c}

Bertil Johansson^a

Departments of ^aClinical Genetics and ^bOncology and the ^cLund Strategic Research Center for Stem Cell Biology and Cell Therapy, Lund University Hospital

SE – 221 85 Lund, Sweden

E-mail address: josef.davidsson@med.lu.se (J Davidsson)

References

- [1] Nowell PC. The clonal evolution of tumor cell populations. *Science* 1976;194:23-8.
- [2] Johansson B, Billström R, Broberg K, Fioretos T, Nilsson P-G, Ahlgren T, Malm C, Samuelsson BO, Mitelman F. Cytogenetic polyclonality in hematologic malignancies. *Genes Chromosomes Cancer* 1999;24:222-9.
- [3] Davidsson J, Paulsson K, Johansson B. Multicolor fluorescence in situ hybridization characterization of cytogenetically polyclonal hematologic malignancies. *Cancer Genet Cytogenet* 2005;163:180-3.
- [4] Saal L.H., Troein C, Vallon-Christersson J, Gruvberger S, Borg Å, Peterson C. Bioarray software environment: A platform for comprehensive management and analysis of microarray data. *Genome Biol.* 2002;3:software0003.1-0003.6
- [5] The Database of Genomic Variants [Internet]. Updated December 2005. Available at <http://projects.tcag.ca/variation/>.

Table 1

Clinical and cytogenetic features of the 6 analyzed myeloid malignancies

Case No.	Sex/age (yrs)	Diagnosis	Karyotype
1 ^a	M/66	AML	47,X,der(Y)t(Y;3)(q12;q21),+8[7]/46,XY,+1,der(1;3)(q10;q10)[3]/46,XY[15]
2	F/36	AML (rel)	46,XX,t(1;6)(q21;p21)[11]/46,XX,t(6;15)(p25;q22)[8]/46,XX[6] ^b
3 ^a	M/49	AML	46,XY,der(18)t(11;18)(q13;p11)[15]/47,XY,+11[6]/46,XY[4]
4	M/77	AML	46,XY,+13,der(13;13)(q10;q10)[8]/47,XY,+13[5]/46,XY[11]
5	F/66	t-MDS	46,XX,del(20)(q11)[5]/46,XX,t(1;8)(q24;p12)[3]/46,XX[14]
6	M/51	t-MDS	46,XY,del(12)(q21q24)[10]/46,XY,+1,der(1;7)(q10;p10)[4]/46,XY[14]

Abbreviations: M, male; F, female; AML, acute myeloid leukemia; rel, relapse; t-MDS, treatment-related myelodysplastic syndrome.

^aThe original karyotypes of cases 1 and 3 have previously been published in [3].

^bNormal karyotype at diagnosis.